Investigation of the Prevalence of Hepatopulmonary Syndrome in Cirrhosis Patients Caused by Hepatitis B in Western China

Overview

to investigate the prevalence of hepatopulmonary syndrome in cirrhosis patients caused by Hepatitis B in western China

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Cross-Sectional
  • Study Primary Completion Date: April 1, 2018

Detailed Description

Hepatopulmonary syndrome (HPS) occurs in approximately 4%-29% of cirrhotic patients and influences mortality. China has 100 million Hepatitis B virus (HBV) carriers and Chronic HBV infection is well-recognized risk factor for cirrhosis.But little is known about the prevalence of HPS in cirrhosis patients caused by HBV in western China. The aim of this study was to investigate the HPS incidence, and the signs, symptoms, arterial blood gas, and BMP9 in the serum of the patients.

Arms, Groups and Cohorts

  • cirrhosis with HPS
    • Diagnosed as HPS
  • cirrhosis without HPS
    • Not Diagnosed as HPS

Clinical Trial Outcome Measures

Primary Measures

  • transthoracic contrast enhanced echocardiography (CEE)
    • Time Frame: During the operation
    • through the ultrasound to evaluate the imagine of cardiac cavity after intravenous injection of agitated saline
  • arterial blood gas
    • Time Frame: During the operation
    • arterial blood gas analysis was performed through the radial artery.
  • medical history
    • Time Frame: During the operation
    • The medical history was collected through consultation.
  • acropachy
    • Time Frame: During the operation
    • acropachy was examined by inspection
  • spider angioma
    • Time Frame: During the operation
    • spider angioma was examined by inspection
  • liver palms
    • Time Frame: During the operation
    • liver palms was examined by inspection
  • oxygen saturation
    • Time Frame: During the operation
    • oxygen saturation was examined by pulse oximetry

Secondary Measures

  • the content of bone morphogenetic protein (BMP9) in the patients with and without HPS
    • Time Frame: 4 to 6 months after the study completion
    • the content and expression of BMP9 were determined by immunohistochemistry.
  • micro ribonucleic acid 144 (miR144), micro ribonucleic acid 200 (miR200) in the patients with and without HPS
    • Time Frame: 4 to 6 months after the study completion
    • the content and expression of BMP9 were determined by polymerase chain reaction (PCR)

Participating in This Clinical Trial

Inclusion Criteria

1. Age: 18-80 years old; 2. American association of anesthesiologists(ASA) score: I-III; 3. Ability to comply with research programmes; 4. Voluntary participation in the study; 5. Has the history of HBV infection; 6. No primary cardiopulmonary disease (heart disease, emphysema, pneumonia, asthma, etc.) Exclusion Criteria:

1. Severe heart, lung, kidney disease coexisted; 2. American association of anesthesiologists(ASA) score≥IV; forced expiratory volume at one second (FEV1) or forced vital capacity (FVC) <70%, or FEV1 / FVC <0.70; 3. Mental state could not cooperate 4. Absence of written informed consent.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 80 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Southwest Hospital, China
  • Provider of Information About this Clinical Study
    • Principal Investigator: Lu KZ, Professor of Institute of Anesthesiology, Southwest Hospital, Third Military Medical University Affiliation: Southwest Hospital, China – Southwest Hospital, China
  • Overall Official(s)
    • Lu K Zhi, PhD, Study Director, Department of Anesthesiology, Southwest Hospital Third Military Medical University
  • Overall Contact(s)
    • Yi Bin, PhD, 0086-02368754197, tang123a123123@163.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.